Exact Sciences (Exact Sciences) Gross Margin % : 73.44% (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Exact Sciences Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Exact Sciences's Gross Profit for the three months ended in Dec. 2023 was $475 Mil. Exact Sciences's Revenue for the three months ended in Dec. 2023 was $647 Mil. Therefore, Exact Sciences's Gross Margin % for the quarter that ended in Dec. 2023 was 73.44%.

The historical rank and industry rank for Exact Sciences's Gross Margin % or its related term are showing as below:

EXAS' s Gross Margin % Range Over the Past 10 Years
Min: -139.15 Med: 73.14 Max: 76.24
Current: 73.83

During the past 13 years, the highest Gross Margin % of Exact Sciences was 76.24%. The lowest was -139.15%. And the median was 73.14%.

EXAS's Gross Margin % is ranked better than
83.8% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 45.44 vs EXAS: 73.83

Exact Sciences had a gross margin of 73.44% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Exact Sciences was -0.50% per year.

Exact Sciences Gross Margin % Historical Data

The historical data trend for Exact Sciences's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Gross Margin % Chart

Exact Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

75.27

76.24

74.04

72.44

73.83

Exact Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															73.39	73.96	74.76	73.18	73.44

Competitive Comparison of Exact Sciences's Gross Margin %

For the Diagnostics & Research subindustry, Exact Sciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exact Sciences's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Exact Sciences's Gross Margin % falls into.

Exact Sciences Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Exact Sciences's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	1845.6	/	2499.766
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(2499.766 - 654.2)	/	2499.766
	=	73.83 %

Exact Sciences's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	475.1	/	646.885
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(646.885 - 171.817)	/	646.885
	=	73.44 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Exact Sciences (NAS:EXAS) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Exact Sciences had a gross margin of 73.44% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Exact Sciences Gross Margin % Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Sciences (Exact Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (NAS:EXAS) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

EXK:Germany

Address

5505 Endeavor Lane, Madison, WI, USA, 53719

Website

https://www.exactsciences.com

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.

Executives

Brian Baranick	officer: Gen. Mgr., Precision Oncology	441 CHARMANY DRIVE, MADISON WI 53719
Sarah Condella	officer: SVP, Human Resources	441 CHARMANY DRIVE, MADISON WI 53719
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Everett Cunningham	officer: Chief Commercial Officer	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Jeffrey Thomas Elliott	officer: Chief Financial Officer	5505 ENDEAVOR LANE, MADISON WI 53719
James Edward Doyle	director	5505 ENDEAVOR LANE, MADISON WI 53719
James Herriott	officer: General Counsel	5505 ENDEAVOR LANE, MADISON WI 53719
Katherine S Zanotti	director	431 E 9TH STREET, HINSDALE IL 60521
Jacob A Orville	officer: General Manager, New Ventures	5505 ENDEAVOR LANE, MADISON WI 53719
Kevin T Conroy	director, officer: Vice President	5505 ENDEAVOR LANE, MADISON WI 53719
D Scott Coward	officer: SVP and General Counsel	441 CHARMANY DRIVE, MADISON WI 53719
Paul J Clancy	director	C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Graham Peter Lidgard	officer: SVP, Chief Scientific Officer	5505 ENDEAVOR LANE, MADISON WI 53719
Michael S Wyzga	director	RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Torsten Hoof	officer: General Manager, International	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063